GTx Inc (GTXI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:GTx Inc (GTXI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9894
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥28,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GTx Inc (GTx) is a biopharmaceutical company that discovers, develops and commercializes novel targeted hormonal therapies. It develops small molecules that targets hormone pathways for the treatment of various cancers including breast and prostate cancer; and other serious medical conditions. The company is further focused on developing selective androgen receptor modulators (SARMs), a class of drugs that have the potential to be used as a hormonal therapy for treating advanced breast cancer and other serious medical conditions, such as stress urinary incontinence (SUI) and Duchenne muscular dystrophy (DMD). GTx is developing enobosarm, a SARM in Phase II trials for treating breast cancer and stress urinary incontinence. GTx is headquartered in Memphis, Tennessee, the US.

GTx Inc (GTXI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GTx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GTx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GTx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GTx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
GTx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GTx Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
GTx Raises USD48.5 Million in Venture Financing 10
Licensing Agreements 11
GTx Enters into Licensing Agreement with University of Tennessee Research Foundation 11
Equity Offering 13
GTx to Raise up to USD50 Million in Public Offering of Shares 13
GTx Plans to Raise Funds through Public Offering of Shares 14
GTx Raises USD48.5 Million in Private Placement of Shares 15
Gtx to Raise USD14 Million in Private Placement of Shares 17
Gtx Raises USD43 Million in Private Placement of Shares and Warrants 18
GTx Completes Private Placement Of Units For US$21.3 Million 20
Asset Transactions 21
ProStrakan Acquires Breast Cancer Product Fareston From GTx For US$22 Million 21
GTx Inc – Key Competitors 22
GTx Inc – Key Employees 23
GTx Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 14, 2018: GTx provides corporate update and reports second quarter 2018 financial results 25
May 15, 2018: GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results 26
Mar 12, 2018: GTx Reports Fourth Quarter and Full Year 2017 Financial Results 28
Nov 14, 2017: GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results 30
Aug 14, 2017: GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results 32
May 15, 2017: GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results 34
Mar 15, 2017: GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
GTx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GTx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GTx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GTx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GTx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
GTx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GTx Raises USD48.5 Million in Venture Financing 10
GTx Enters into Licensing Agreement with University of Tennessee Research Foundation 11
GTx to Raise up to USD50 Million in Public Offering of Shares 13
GTx Plans to Raise Funds through Public Offering of Shares 14
GTx Raises USD48.5 Million in Private Placement of Shares 15
Gtx to Raise USD14 Million in Private Placement of Shares 17
Gtx Raises USD43 Million in Private Placement of Shares and Warrants 18
GTx Completes Private Placement Of Units For US$21.3 Million 20
ProStrakan Acquires Breast Cancer Product Fareston From GTx For US$22 Million 21
GTx Inc, Key Competitors 22
GTx Inc, Key Employees 23

List of Figures
GTx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GTx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GTx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GTx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GTx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
GTx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GTx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[GTx Inc (GTXI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Indo-National Limited (NIPPOBATRY):企業概要、財務及び戦略的SWOT分析
    Summary Indo-National Limited (Indo-National), formerly Nippo Batteries Co. Ltd., is a batteries manufacturing company. The company designs, produces and commercializes batteries and related products. It offers product under three categories, including rechargeable, non-rechargeable and solar powere …
  • ArcDia International Oy Ltd:企業のM&A・提携動向(医療機器分野)
    Summary ArcDia International Oy Ltd (ArcDia International) is an in vitro diagnostic company that develops products for the rapid testing of infectious diseases. Its major products include mariPOC test system, an automated system for the rapid multianalyte identification of acute infectious diseases …
  • COSMOS Pharmaceutical Corporation:企業の戦略・SWOT・財務分析
    SummaryCOSMOS Pharmaceutical Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the co …
  • Noevir Holdings Co., Ltd. (4928):企業の財務及び戦略的SWOT分析
    Summary Noevir Holdings Co., Ltd. (Noevir), a subsidiary of Noevir Co. Ltd is a health and beauty product company that develops, produces and sells cosmetics, pharmaceuticals, health food and other products. The company offers cosmetics such as skincare products and hypoallergenic cosmetics. Noevir …
  • DFDS A/S:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' DFDS A/S Mergers and Acquisitio …
  • PostNL N.V.:企業の戦略・SWOT・財務分析
    PostNL N.V. - Strategy, SWOT and Corporate Finance Report Summary PostNL N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Pryme Energy Limited (PYM)(石油・ガス分野):企業M&A動向
    Summary Pryme Energy Limited (Pryme) is an oil and gas exploration company. The company conducts acquisition, up-gradation, exploration and production activities of onshore oil and natural gas in the Southern US. Its products include crude oil and natural gas. Pryme undertakes the project located in …
  • Medtecs International Corporation Limited (546):企業の財務及び戦略的SWOT分析
    Summary Medtecs International Corporation Limited (Medtecs) is a medical device company that manufactures and distributes medical consumable products. The company offers products such as linen, hospitality apparel and bandages. It also offers anti-static surgical attire, bandages, underpads, surgica …
  • Vivakor Inc (VIVK):企業のM&A・提携動向(医療分野)
    Summary Vivakor Inc (Vivakor) is a technology and asset acquisition company that creates, acquires and accumulates distinct assets, intellectual properties, and various technologies. The company concentrates on precious metals extraction in the US. It also concentrates on oil extraction from shallow …
  • Logitech International SA:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Logitech International SA Merge …
  • Lantheus Medical Imaging, Inc.:企業のM&A・提携動向(医療機器分野)
    Summary Lantheus Medical Imaging, Inc. (Lantheus Medical), formerly Bristol-Myers Squibb Medical Imaging, Inc., develops, manufactures, and commercializes medical imaging agents. Its major products include medical radiopharmaceuticals (including technetium generators) and contrast agents. The compan …
  • Fate Therapeutics, Inc. (FATE)(製薬・医療分野):企業M&A動向
    Summary Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of adult stem cell pharmacologic modulators for the patients with rare life threatening disorders. The company has developed two platforms, namely, HSC Modul …
  • WPPI Energy, Inc.:企業の戦略的SWOT分析
    WPPI Energy, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Soft Tissue Regeneration Inc:企業のM&A・提携動向(医療機器分野)
    Summary Soft Tissue Regeneration Inc (STR) is a medical device company that develops technology for soft tissue regeneration of the anterior cruciate ligament of the knee. The company concentrates on the application of resorbable polymer scaffold technology to regenerate and repair ligament and tend …
  • MarkWest Energy Partners, L.P. (MWE):企業のM&A・提携動向(石油・ガス分野)
    Summary MarkWest Energy Partners, L.P. (MarkWest Energy) is a midstream energy company. It carries out the gathering, processing, transportation of natural gas; the transportation, fractionation, storage, and marketing of natural gas liquids (NGLs); and the gathering and transportation of crude oil. …
  • GRP Limited (G18):企業概要、財務及び戦略的SWOT分析
    Summary GRP Limited (GRP) is an equipment manufacturing company. The company’s business operations include GRP hose and marine specialists, region suppliers for measuring instruments, metrology, and GRP China's uPVC pipes and fittings. Its hose and marine specialists manufacture and supplies hose an …
  • JF Hillebrand Group AG:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' JF Hillebrand Group AG Mergers …
  • Artfest International, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Artfest International, Inc. Mer …
  • Alimentation Couche-Tard Inc (ATD.B):石油・ガス:M&Aディール及び事業提携情報
    Summary Alimentation Couche-Tard Inc (Couche-Tard) is a retail company that operates an extensive network of convenience stores. The company principally offers food and non-food items as well as transportation fuels. Couche-Tard products include tobacco, alcohol, grocery items, candy, snacks and var …
  • Empire Resorts, Inc.:企業概要・SWOT・財務分析
    Summary Canadean's "Empire Resorts, Inc. : Travel and Tourism - Company Profile, SWOT and Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business descript …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆